This trial will test a new antibody drug, ICT01, either alone or in combination with another drug, pembrolizumab, in patients with advanced solid or blood cancers.
- Solid Tumors, Adult
- Blood Cancer
4 Primary · 8 Secondary · Reporting Duration: 12 months
Awards & Highlights
2 Treatment Groups
IV ICT01 Monotherapy
1 of 2
IV ICT01 + IV Pembrolizumab
1 of 2
150 Total Participants · 2 Treatment Groups
Primary Treatment: IV ICT01 · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the target outcome of this experimental endeavor?
"This 12-month clinical trial will measure its primary outcome, Disease Control Rate using RECIST for solid tumor patients (Part 2), and several secondary outcomes such as Change from Baseline in the Number of Circulating Gamma Delta T Cells, Half-life of ICT01, and Objective Response Rate using RECIST for solid tumor patients (Part 2)." - Anonymous Online Contributor
What is the total participant capacity of this clinical trial?
"Affirmative. According to clinicaltrials.gov, this investigation is currently recruiting volunteers with the initial posting on February 10th 2020 and most recent update on October 5th 2022. 150 participants are needed from a single location to complete the trial." - Anonymous Online Contributor
Is enrollment currently open for this experiment?
"Based on what is available through clinicaltrials.gov, this study is still enrolling participants. It was initially posted back in February 10th 2020 and has since been modified as recently as October 5th 2022." - Anonymous Online Contributor